2024-06-26

Q: Tell us about PBL’s latest offerings and how did PBL's expertise contribute to the innovation of the CF Box?

Filippo Begarani: PBL is an Italian Innovative SME, born in 2018 as a Start-up, whose core business is the design and realization of customized industrial production lines for the pharmaceutical sectors. PBL is a fast-growing reality leader in pharmaceutical automation and AI-based inspection of pharmaceutical products, being also cited in Sole24Ore and Financial Times rankings of the most promising fast-growing companies in Italy and Europe.

PBL contributed to creating CF Box as an extremely innovative automated machine for Cell and Gene Therapy using its long-term core expertise in pharmaceutical automation, Artificial Intelligence and Deep Learning for inspection, to adapt to any medical need and market request.

Q: What is the USP of the CF Box for CAGT manufacturing from PBL's perspective and how does PBL address the need for high reproducibility in the CF Box?

Filippo Begarani: CF Box represents an innovative solution for the Cell and Gene Therapy field since it can automatize any manual process required for ATMPs manufacturing, which are so far very demanding, complex and expensive. It aims to be totally flexible and easily adaptable to any modification required from the user. CF Box represents an innovative solution also giving the possibility to install and implement third-parties instrumentations which could be required from specific customers for ATMPs production.

The USP of the CF Box is also represented by the “All-inclusive” technical support which could be given to every potential customer, who also requires consulting service to start or upgrade his ATMPs production using this technology.

Q: How does the CF Box align with PBL's mission and vision and PBL’s role in the recent collaboration with ProPharma?

Filippo Begarani: The CF Box represents a terrific opportunity for PBL as a ground-breaking project for the pharma industry. Its realization is in line with PBL mission of creating customizable and flexible solution for pharmaceutical industry, automatizing processes according to customer needs. In this case, the solution of PBL envisages the goal of making ATMPs widespread and next-to-the-patient therapies, representing CF Box an opportunity to improve cell and gene therapies evolution thanks to the process scalability and automatization it empowers.      

Q: How does PBL ensure the CF Box remains adaptable to future technological advancements?

Filippo Begarani: PBL is a leading company in creating flexible and customized solutions for pharmaceutical industry, with high adaptability on each clients’ requirement. With all its expertise, PBL is willing to realize every type of automatization improvement, evolving and adapting its ground-breaking proposed CF Box solution to all the most complex tech challenges and to the healthcare unmet needs.